Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 150%
The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.
Brief by WorldPing · Original reporting by CNBC World
WorldPing



